Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. - Wikidata - awgldk - TriplyDB

Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia.

Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia.

http://www.wikidata.org/entity/Q33348256

about

Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies.Diagnosis and management of heparin-induced thrombocytopenia.Bivalirudin: a review.Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia.Heparin-induced thrombocytopenia: treatment options and special considerations.Heparin-induced thrombocytopenia and recent advances in its therapy.Current concepts review: heparin-induced thrombocytopenia.Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization.Fondaparinux: does it cause HIT? Can it treat HIT?An overview of heparin-induced thrombocytopenia.Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series.The Pharmacotherapy of Heparin-Induced Thrombocytopenia (HIT) : A Review of Contemporary Therapeutic Challenges in Clinical Practice.Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician.Heparin-induced thrombocytopenia in the pediatric population: a review of current literature Pulmonary embolism caused by delayed heparin-induced thrombocytopenia in a patient who received prophylactic LMWH.Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system Low-molecular-weight heparin for the treatment of venous thromboembolism in the elderly.Superficial vein thrombosis.Anticoagulation in pregnancy: a survey of current practice.Can heparin-induced thrombocytopenia be associated with fondaparinux use? A rebuttal.Development of antibodies specific to polyanion-modified platelet factor 4 during treatment with fondaparinux.Widespread skin necrosis associated with unfractionated heparin therapy in a patient under chronic coumarin anticoagulation.The immunogenic potential of generic version of low-molecular-weight heparins may not be the same as the branded products.

P2860

Q33365296-CE9B59E1-DA1C-403D-ACD9-7D3041AF6990 Q33365985-F9A55E95-7C6C-4143-ABBC-A3D56A6ADB66 Q33367230-EC82DA40-6C27-4219-BB08-0076619927CA Q33374563-3F131A00-BDE2-4317-8AC2-A3680DCACB9F Q33374658-2BF122F6-84EB-4166-8656-772F98BB8586 Q33377436-1DD55E71-80DE-4063-9784-054D04216A2C Q33382108-B3CC7AF9-5795-4758-9B82-3D8CE437B29A Q33387713-C36CCF76-50F0-4F1C-81C0-9AB5BFC13731 Q33392864-82522AB6-14F9-4B93-A564-77E96CAE9B8B Q33394986-13B31202-1F77-4B1B-9B55-C89CF387F139 Q33396967-20769C93-36CC-4A0E-AC21-DC18DDB387B8 Q33401236-C1F0968C-F2CC-4E74-8203-9F4D891CCCF3 Q33402572-829A0184-6609-444B-A0AD-754C8AB3DD7D Q33404178-7FE083DA-79F2-45B1-A2A9-E2D06E2BF5AE Q33406965-1C7CCB10-1520-470D-9002-280A0DD4AC45 Q33418994-80047C4E-1CEF-4DC2-ADCC-005217B1D834 Q36022983-96ABF726-30C1-47B9-B10D-6DC71B4070AD Q43905870-FA80318C-38D8-4BF8-B46C-9C8D568E220D Q44693251-963AC20F-CF7F-4812-AD7C-04B8743A33C6 Q46069546-4F8EC6B1-8BFC-4789-B1CD-35F0FBBD5695 Q46855028-30F90442-C032-4775-B4CD-3387F6F54270 Q46965139-9B435BD9-C181-4C8E-9C41-5E1B2B7C8705 Q47253148-0764088D-9BDC-4B84-B8F0-73A98BFBEEE9

P2860

Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia.

http://www.wikidata.org/entity/Q33348256

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Biological and clinical featur ...... arin-induced thrombocytopenia.

@ast

Biological and clinical featur ...... arin-induced thrombocytopenia.

@en

type

label

Biological and clinical featur ...... arin-induced thrombocytopenia.

@ast

Biological and clinical featur ...... arin-induced thrombocytopenia.

@en

prefLabel

Biological and clinical featur ...... arin-induced thrombocytopenia.

@ast

Biological and clinical featur ...... arin-induced thrombocytopenia.

@en

P1433

Q33348256-C999C705-D004-4BB1-8DB5-0ADEB658945F

P1476

Q33348256-E85EC923-7BFE-42DA-BDBD-C8D75F63FD06

P2093

Q33348256-3B4977E0-DC70-4708-B92D-B9DCEB317508

Q33348256-4986CA5C-695A-4A8C-ACEE-1CCCF2E97018

Q33348256-56C9A9A9-2AA6-4EBB-A1BB-CC043AAA23EE

Q33348256-87D34239-9191-49B7-B331-C3495B5AC89A

Q33348256-96932305-2921-4E2B-8FB7-0BB9F0C1A04F

Q33348256-A06B4D05-9B8C-43CA-895B-9F00B3ECEF8A

Q33348256-AFFE0245-BD8A-4B4A-BDDE-444BF9F306C2

Q33348256-B3448AD6-ACE8-4270-AE47-44A90C4D4F86

Q33348256-E75B5CE9-1D1D-4FE3-9662-AEC75B86C63C

P2860

Q33348256-01BAEB03-3865-4AEE-8231-BAEBC6DB6920

Q33348256-5AF48F6B-A5B8-4A3C-BE4A-F2B15013DDF1

Q33348256-6A1E9F31-7E60-44DE-86F3-0A6DF7D01BD3

Q33348256-7FB01D57-E44E-4138-9B44-9F32DBA6A28E

Q33348256-83D2B591-26A9-4629-83C6-18B2530BDD9D

Q33348256-B60707FA-9488-4A77-8A8D-F435B6B9B7AE

Q33348256-C3C3395B-3251-41C0-A9E8-A3730EE5166A

Q33348256-E5329C58-FBCE-4DFD-BBEC-AB05F9C48C69

Q33348256-E63B7E51-CBA0-41E5-B235-A157F0F7874B

Q33348256-E870C239-4009-4F3F-8C42-BAF4E5135C08

P304

Q33348256-70708844-6829-45BA-A3AF-2538093C20C1

P31

Q33348256-A3F6F2A2-DA5C-42F3-9085-ADAF18E0348C

P356

Q33348256-AA9F3D16-BD56-4AC2-A069-2844A6C04EC0

P407

Q33348256-82285652-AA25-4CC3-9613-7226567FEB41

P433

Q33348256-03AD923A-42C0-4296-A9CC-D84A9D40982C

P478

Q33348256-6F965511-B68A-4699-9578-B4C4DBFC92EC

P577

Q33348256-E4E91C1D-0FA9-4D6A-AEFB-5A28650D6354

P5875

Q33348256-D1B552B9-A47C-488A-9BFE-4A7F59ED8A82

P698

Q33348256-40A3FB46-4A40-4373-A0A0-A03B922791B4

P921

Q33348256-9FFBF2A5-168C-4DDD-8EE2-856E5A0AC859

P356

J.1365-2141.2003.04363.X

P1433

British Journal of Haematology

P1476

Biological and clinical featur ...... arin-induced thrombocytopenia.

@en

P2093

Annie Derlon

http://www.w3.org/2001/XMLSchema#string

Claire Pouplard

http://www.w3.org/2001/XMLSchema#string

French Heparin-Induced Thrombocytopenia Study Group

http://www.w3.org/2001/XMLSchema#string

Irène Juhan-Vague

http://www.w3.org/2001/XMLSchema#string

Jeanne-Yvonne Borg

http://www.w3.org/2001/XMLSchema#string

Michel Samama

http://www.w3.org/2001/XMLSchema#string

Philippe Nguyen

http://www.w3.org/2001/XMLSchema#string

Véronique Regnault

http://www.w3.org/2001/XMLSchema#string

Yves Gruel

http://www.w3.org/2001/XMLSchema#string

P2860

Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia.

Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia.

Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.

Temporal aspects of heparin-induced thrombocytopenia.

Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin.

Heparin-associated thrombocytopenia.

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.

Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin.

A 14-year study of heparin-induced thrombocytopenia.

Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium.

P304

786-792

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2141.2003.04363.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P577

2003-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10730343

http://www.w3.org/2001/XMLSchema#string

P698

12780795

http://www.w3.org/2001/XMLSchema#string

P921

thrombocytopenia